Edwards Lifesciences Corporation
EW
$86.67
-$0.08-0.09%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -- | -9.04% | 1.73% | 4.24% | -- |
| Total Depreciation and Amortization | -- | -3.79% | -4.94% | 16.08% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | 1,048.94% | -27.52% | -71.80% | -- |
| Change in Net Operating Assets | -- | -581.20% | 73.15% | -114.30% | -- |
| Cash from Operations | 63.08% | -21.88% | 624.11% | -193.34% | -14.51% |
| Capital Expenditure | -- | 42.27% | 14.24% | 43.60% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -748.26% | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -158.42% | 10.05% | -505.50% | -- |
| Cash from Investing | -115.83% | -237.90% | 35.18% | -4,190.07% | 2,935.62% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 5.34% | -19.65% | -13.86% | -- |
| Repurchase of Common Stock | -- | 96.52% | -154,200.00% | 99.98% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -86.11% | 450.00% | -95.00% | -- |
| Cash from Financing | 24.22% | 154.55% | -518.15% | 106.92% | -581.58% |
| Foreign Exchange rate Adjustments | -- | -200.68% | -282.47% | 1,600.00% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -129.39% | -67.09% | 11.11% | -134.90% | 452.76% |